Report of Foreign Issuer (6-k)
September 13 2016 - 7:13AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of September 2016
001-36203
(Commission
File Number)
CAN-FITE BIOPHARMA LTD.
(Exact
name of Registrant as specified in its charter)
10
Bareket Street
KiryatMatalon,
P.O. Box 7537
Petach-Tikva
4951778, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover
Form 20-F
or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(7): ____
This
Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant's Registration Statements
on Form F-3 (File Nos. 333-195124, 333-199033, 333-204795 and 333-209037), to be a part thereof from the date on which this report
is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On
September 13, 2016, Can-Fite BioPharma Ltd. issued a press release announcing that it has received a Notice of Allowance from
the European Patent Office indicating the patent titled, “Pharmaceutical Composition Comprising A3 Adenosine Receptor Agonist
(IB-MECA/CF-101) for Treatment of Psoriasis” will be granted. A copy of this press release is attached hereto as Exhibit
99.1 and is incorporated herein by reference.
Exhibit
Index
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated September 13, 2016
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Can-FiteBioPharma
Ltd.
|
|
|
|
Date:
September 13, 2016
|
By:
|
/s/
Pnina Fishman
|
|
|
Pnina
Fishman
|
|
|
Chief
Executive Officer
|
4
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2024 to May 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From May 2023 to May 2024